VEGFA and breast carcinoma: Given the association between increased VEGF-receptor 2 expression in TN breast cancer [31], targeting TN breast cancer with Sunitinib or the anti-VEGF agent Bevacizumab may be a more effective approach and these clinical trials are now ongoing [30,32].